Matt Henriksen

My math got to six or seven sensors per user, which is coming back to like one sensor per quarter per patient.

That's kind of my thought process for those who are not using insulin.

Because, you know, you just need to make sure that, you know, your trends are going, long-term trends are on track.

You're not progressing, as you're saying.

Your progression is not accelerating to a point where you need insulin.

What are your thoughts about that kind of one sensor per quarter for those non-insulin patients?

Am I in the right ballpark?

Or are you thinking that this is an expansion strategy beyond one per quarter?

Yeah.

Well, it's very interesting because actually I have a stello and I've been meaning to try it.

And I was going to try it maybe before this conversation, but I also knew it was earning season.

And I also know I eat more candy during earning season, especially late at night.

And I'm like, I don't want to see that spike yet during earning season on my stello yet.

So I get that accountability.

uh, platform.

And so, you know, we were talking about, and like one of the things that we're talking about with this too, is the, just the reimbursement.

And this is just, you're, you're seeing how these patients are interacting with the stello, they're purchasing patterns without reimbursement.

And it's interesting because you are preparing a randomized trial, which if I did my math right, was, it might be presented this ADA in June and, um,

I'm just curious, the trial design, because it also seems like you had the landmark diamond trial in 2016.

You had the landmark mobile RCT trial in 2021, which coincidentally just lines up with all these snowstorms that we're getting in New York.